Director of Oncology Department, Wugang People’s Hospital, Shaoyang, Hunan Province Today, he is very happy to see that a patient with ovarian cancer who has been suffering for many years has finally used the PARP inhibitor niraparib. This patient had undergone ovarian cancer surgery and chemotherapy, and had a partial response to platinum-sensitive recurrence after comprehensive treatment. And Dr. Yang found a completely corresponding case in the case study area of Yimaitong Xiaole (Gynecologic Oncology) Digital Area. It was through the guidance of the senior experts in the case that he strengthened his confidence in using PARP inhibitors for maintenance treatment of patients.
/p>
Dr. Yang has a certain number of ovarian cancer patients every year. He hopes to grasp the latest academic progress of ovarian cancer through convenient and reliable information channels. At least, he can only get some scattered academic information. Due to the lack of systematic study and experience in diagnosing complex cases, when encountering patients with similar conditions, Dr. Yang can only recommend patients to go to higher-level hospitals.
/p>
This situation changed as he registered in the Medical Mai Tong Xiaole Zone. Xiaole Zone is an online academic platform for grassroots doctors launched by Yimaitong and Zai Lab. The platform will push the latest academic information on ovarian cancer and live broadcast of academic lectures for every registered doctor. Doctors can also use The AI question-and-answer assistant in the zone solves practical clinical problems and conducts in-depth learning by watching reviews of real cases.
Not only this, but also by Dr. Yang through the platform I learned about the “Leading Wild Goose Program” initiated by China Obstetrics and Gynecology Online and Xiangya Hospital of Central South University, and I will learn systematic courses such as ovarian cancer surgery, chemotherapy, maintenance treatment, and nutritional support face-to-face with the expert director of the gynecological oncology department of the hospital.
A pure online platform, Yimaitong Xiaole Zone has reached a strategic cooperation with the largest local pharmaceutical distributor, Sinopharm Hunan. Sinopharm Hunan has local staff. When the patient reaches the medication stage, Sinopharm Hunan not only assists in completing the last mile drug delivery, but also provides medication guidance and follow-up for local patients through the pharmacist service of the DTP pharmacy. At present, it is further assisting in creating a model of upper and lower graded diagnosis and treatment.
The above scenario is through Yimaitong platform + Zai Lab + Guokong Hunan< /strong>provides an overall closed-loop service for doctors, and such cases are happening every day in 11 provinces across the country from April 2021: including Anhui, Shandong, Hubei, Guangxi, Hunan, Sichuan , Jiangxi, Shanxi, Heilongjiang, Liaoning, Jilin.
At the end of 2020, Zai Lab’s national class 1 new drugs won two national “Thirteenth Five-Year Plan” “Major New Drug Creation” major scientific and technological projects The project-supported product niraparib, the indication for maintenance treatment of platinum-sensitive recurrent ovarian cancer has been included in the National Medical Insurance Drug List (2021), and the indication for maintenance treatment of niraparib for the first-line population of ovarian cancer by the end of 2021 will be expanded to be included in the national medical insurance drug Catalogue (2022), not only has become the PARP inhibitor with the lowest average daily treatment cost, but has also become the only PARP inhibitor that can benefit from maintenance therapy in the first-line population (regardless of whether BRCA is mutated or not). Prior to this, first-line ovarian cancer In the field of maintenance therapy, products in other medical insurance catalogues are only suitable for patients with BRCA mutations, and these patients account for only 15%-25% of all ovarian cancer patients.
This indicates that more patients in fourth- and fifth-tier cities and below will be able to afford niraparib and benefit earlier, but Hospitals and doctors in these regions have almost no knowledge of innovative tumor drugs with new mechanisms such as PARP inhibitors.The use of PARP inhibitors involves surgery, chemotherapy, radiotherapy, maintenance therapy, and management of side effects. There are still many obstacles for doctors to prescribe them, and it is even more difficult for patients to conveniently use innovative drugs at their doorsteps.
width=” p>
“Patient-centered” should be consistent throughout the drug development and commercialization process. Thanks to our country’s policy support, in the foreseeable future, there will be more and more products like Nirapari. The lack of the product has become a bottleneck for the wide application of the product. The improvement of the academic level of Chinese grassroots doctors must be inseparable from the continuous improvement of the medical and health system, and the three-party in-depth cooperation such as ZAILINK, the manufacturer’s academic + platform technology + dealer’s offline service model, It is also at the forefront of innovation with its own practical actions.
By Yimaitong